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constitutes a relatively new biotechnology that has been
a breakthrough in the stimulation and acceleration of
soft-tissue and bone healing. The efficiency of this
process lies in the local and continuous delivery of a
wide range of growth factors and proteins, mimicking
the needs of the physiological wound healing and
reparative tissue processes. Consequently, the appli-
cation of platelet-rich plasma has been extended to
many different fields, including orthopedics, sports
medicine, dentistry, cosmetic and periodontal medicine
and cosmetic, plastic and maxillofacial surgery. This
article highlights the use of this technology and
discusses some of the obstacles and challenges that
need to be addressed to maintain progress in this field.
Introduction: demand for musculoskeletal care
Musculoskeletal disorders are a major cause of morbidity
throughout the world. They have a substantial impact on
quality of life, including disability, with widespread
economic consequences [1]. The severity of this problem
is illustrated by the increasing number of patients
suffering from articular diseases and osteoporotic frac-
tures [2]. In addition, musculoskeletal injuries derived
from sports activities and road traffic accidents also
contribute to the escalation of social and financial costs
[3]. As a result of this, the period between the years 2000
and 2010 has been named the decade of bone and joint, as
an international initiative to promote and advance
research on prevention, diagnosis and treatment [4].
Although a wide range of therapeutic options are
available, several important drawbacks need to be
addressed. For example, in the case of bone defects and
lesions, although autologous bone autografts are the
preferred treatment, the supply of suitable bone is limited
and its collection is painful and carries a risk of infection,
nerve damage and hemorrhage [5]. With articular
injuries, such as osteoarthrosis, treatments other than
surgery are palliative and do not modify the progression of
the disease. Finally, in the case of muscle lesions the RICECorresponding author: Andı́a, I. (isabel.andia@bti-imasd.com).
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applied in combination with non-steroidal anti-inflamma-
tory drugs but, unfortunately, there is still a high rate of
injury recurrence [6]. Considerable research and clinical
efforts are being made to accelerate tissue healing and to
improve the therapeutic treatments for these
musculoskeletal disorders.Growth factors and healing mechanisms
It is generally accepted that growth factors have an
essential role in the healing process and tissue formation
[7]. In fact, all stages of the repair process are controlled by
a wide variety of cytokines and growth factors acting
locally as regulators of the most basic cell functions, using
endocrine, paracrine, autocrine and intracrine mechan-
isms. Growth factors influence many of the processes
common to both tissue repair and disease, including
angiogenesis, chemotaxis and cell proliferation; they also
control the synthesis and degradation of extracellular
matrix proteins. Their mode of action is to bind to the
extracellular domain of a target growth-factor-receptor
that, in turn, activates the intracellular signal-transduc-
tion pathways [8,9]. The elucidation of some of the
functions of growth factors in tissue repair has led to the
conclusion that their controlled temporal expression is
crucial following surgical interventions and in the
treatment of musculoskeletal disorders, including bone
fractures, cartilage defects and muscle and tendon lesions
(Figure 1) [10].
These findings have led to a significant research effort
aimed at testing different growth factors and cytokines as
therapeutic molecules for the repair or regeneration of a
wide range of tissues [11]. The molecules that have been
most intensively investigated in orthopedic research
include bone morphogenetic proteins (BMPs), transform-
ing growth factor-b (TGF-b), platelet-derived growth
factor (PDGF), insulin-like growth factor (IGF), vascular
endothelial growth factor (VEGF) and fibroblast growth
factors (FGF). However, despite promising results from
the early animal [12,13] and small-scale clinical studies
[14], few large-scale clinical trials have been performed
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Figure 1. Injured Achilles tendon in a sheep model. Histological sections illustrate the different stages of the healing process, where growth factors are crucial regulators of
cell functions. A platelet-rich fibrin scaffold enhances the natural process because it permits the progressive and balanced release of a large pool of molecules, including
growth factors and other cytokines, mimicking the physiological process of repair.
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ated in a collagen sponge, have been approved by several
federal agencies for the treatment of long bone fractures.
Unfortunately, besides these two products, no other
growth factor is, at present, commercially available for
clinical applications in the enhancement of bone
regeneration [10].
Limiting factors in the current efforts are related to both
the mode of growth factor delivery and the requirements
for multiple signals to drive the regeneration process to
completion. The latter is essential, assuming that no single
exogenous agent can mediate, effectively, all aspects
needed for tissue repair. Thus, delivery of a wide range of
biological mediators is required if complete tissue engin-
eering is to be achieved. Furthermore, the way these
growth factors are made available is of paramount
importance. Ideally, they should be delivered locally,
following specific and distinct kinetics, to mimic, as far as
possible, the requirements of the injured tissue during the
different regenerationphases in situ [16]. Thedevelopment
of easy, non-toxic, safe and cheap therapeutic alternatives,
whichmight result in the local release of growth factors for
the treatment of musculoskeletal disorders and mimic
natural expression patterns, is becoming the ‘holy grail’ of
orthopedic, medical and pharmaceutical researchers.Platelet-rich plasma
Platelets contribute to haemostasis by preventing blood
loss at sites of vascular injury, and they contain a largewww.sciencedirect.comnumber of growth factors and cytokines that have a key
role in bone regeneration and soft-tissue maturation. In
the past two decades, an increased understanding of the
physiological roles of platelets in wound healing and after
tissue injury has led to the idea of using platelets as
therapeutic tools. Indeed, after fibrin glue was introduced
in the early 1990s as a biomaterial with haemostatic and
adhesive properties, the strategic modification of the fibrin
to include platelets was reported [17]. The source of the
new preparation, known as platelet-rich plasma (PRP),
consists of a limited volume of plasma enriched in
platelets, which is obtained from the patient. Once the
platelet concentrate is activated by way of thrombin
generation with calcium, a three-dimensional and bio-
compatible fibrin scaffold is formed (Figure 2), and a
myriad of growth factors and proteins are released,
progressively, to the local environment, contributing to
the accelerated postoperative wound healing and tissue
repair [18]. Furthermore, this preparation promotes rapid
vascularization of the healing tissue and, because it is
autologous, it eliminates concerns about immunogenic
reactions and disease transmission [19]. Consequently,
the use of autologous PRP as a novel therapeutic
alternative opens new avenues in other fields such as
orthopedics, sports medicine, dentistry, periodontal sur-
gery and plastic and maxillofacial surgery.
However, there are controversies in the literature
regarding the potential benefits of this procedure. In
fact, although some authors have reported significant
(a)
(b) (c)
Figure 2. Activation of platelet-rich plasma with calcium brings about thrombin generation and platelet aggregation and the development of a fibrin scaffold. (a) Photograph
showing the platelet rich fibrin scaffold (barZ5 mm). (b) Structure of the platelet-rich fibrin clot as seen by fluorescence microscopy showing a network of fibrin strands
(green fluorescence) and platelets aggregates (red–yellow fluorescence) (barZ40 mm). (c) Transmission electron micrograph of a platelet aggregate showing signs of
activation, including the centralization of granules and pseudopod extrusion (arrow).
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platelet-rich plasma [20–22], others failed to observe
improvement [23–25]. Such discrepancies are probably
related to the lack of suitable standardization and
definition of the different PRP preparations; the protocols
and biological and surgical techniques used in the
elaboration and administration of the PRPs differ widely
[26,27]. Variations in some key properties of the PRPs,
including the platelet concentration, the type of clot
activator, the leukocyte content and the time that the
fibrin scaffold is put into place around the tissue after
clotting has started can influence the different biological
effects markedly.
For more than a decade our group has studied the
characteristics and the potential impact of the different
variables on the use of platelet-rich preparations in
healing. These efforts have given rise to an optimized
and safer product known as ‘preparation rich in growth
factors’ (PRGF), which circumvents many of thewww.sciencedirect.comlimitations of other reported PRPs [21]. For example,
sodium citrate and calcium chloride are used as an
anticoagulant and a clot activator, respectively. Addition
of calcium chloride promotes the formation of native
thrombin, mimicking the physiological clotting process
and enabling a more sustained release of growth factors,
which might be crucial to proper tissue repair and wound
healing [28]. Moreover, this procedure obviates immuno-
logical reactions and the risk of disease transmission
associated with the use of exogenous bovine thrombin [29].
PRGF contains a moderately elevated platelet concen-
tration ofw6!105 platelets/ml, which has been reported to
induce the optimal biological benefit [30]. In fact, lower
platelet concentrations can lead to suboptimal effects,
whereas higher concentrations might have an inhibitory
effect [30]. Finally, in the quest for a safer and more
effective product, PRGF does not contain leukocytes, thus
improving the homogeneity of the product and reducing
donor-to-donor variability [26]. The former is particularly
Review TRENDS in Biotechnology Vol.24 No.5 May 2006230relevant because neutrophils express matrix-degrading
enzymes, such as matrix metalloproteinases-8 (MMP-8)
and MMP-9, and release reactive oxygen species that
destroy all surrounding cells, whether injured or
healthy [31].
Therapeutic applications
The therapeutic administration of PRP extends to the
treatment of multiple musculoskeletal disorders and to
the regeneration and healing of a wide range of tissues
(Figure 3). Below, we summarize recent advances in the
field, and address some challenges that need to be
considered if progress in the use of this technology is to
be maintained.
Bone
More than 6 million bone fractures are reported annually
in the USA, of which in the range of 5–10% have impaired
healing that causes pain and disability. As a result,
scientists are making great efforts both to create bone
substitutes and to develop ways of improving bone
healing. To succeed, any substitute should be biologically
compatible, non-toxic, provide scaffolding for angiogenesis(a) (b)
(c) (d)
(e)
Figure 3. Preparations rich in growth factors (PRGF) are used in a variety of therapeutic ap
microscopy reveals osteoblast filopodia on the surface of titanium implants bioactivated
alveolus so as to enhance bone regeneration. (c) Transfer of autologous growth factors to
necrotic skin ulcer with PRGF. (e) Surgical repair of an Achilles tendon rupture assisted
www.sciencedirect.comand new bone outgrowth, osteogenic, resorbable, micro-
porous and easy to handle. Furthermore, it should
combine osteoconductive and osteoinductive properties.
The use of PRP helps to fulfill some of these
requirements, particularly as an aid to bone regeneration.
In fact, in vitro studies have demonstrated, clearly, that
platelet-derived growth factors stimulate the proliferation
of both human trabecular bone cells [32] and human
osteoblast-like cells [33]. Initial in vivo experiments
involving PRP were reported in the field of oral-
maxillofacial surgery and in dentistry, particularly in
periodontal therapy. Marx and co-workers studied the
potential effect of autologous PRP on a bone graft
reconstruction of mandibular continuity defects, conclud-
ing that the combination of PRP and bone grafts resulted
in a significantly faster maturation and histomorphome-
trically denser bone regeneration [20]. In a study
involving 20 patients who underwent tooth extraction
because of periodontal disease or vertical fractures, we
evaluated the effect of PRGF alone and in combination
with autogenous bone. Results showed that in most of the
patients receiving PRGF, bone regeneration was extensive
and the bone tissue was compact with well-organizedplications. (a)One of the roles offibrin is to promote cell adhesion; scanning electron
with PRGF. (b) Dental implantology: platelet-rich fibrin applied to a post-extraction
a tendon graft used to reconstruct an anterior cruciate ligament. (d) Treatment of a
with PRGF.
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and little mature bone were found [21].
One exciting focus of interest lies in the combination of
PRGF and bone implants to facilitate the anchorage of
dental prostheses. This has been investigated, widely, by
our group, both in animal models and in humans, where
the surface of the titanium implants are coated with PRGF
before insertion in the host tissue [34,35]. Results showed
that the extent and quality of bone regeneration around
the implant is significantly improved when this PRGF-
based strategy is used. In part, this is because the latter
bioactivates the implant surface, facilitating the inter-
action of the implant with the host tissue, thus enhancing
both the initial stability of the implants and their
subsequent osteointegration. Other groups have also
reported substantial benefits after combining the dental
implants with platelet-derived preparations [36]. In
addition, a single application of PRGF before placement
of the implant can be sufficient to increase the percentage
of bone-to-implant contact in cortical bone [37].
Once PRGF is activated, a considerable number of
growth factors and proteins, with potentially key roles in
bone healing and remodeling, are released from platelets,
including TGF-b1, PDGF, IGF, bone sialoprotein, throm-
bospondin and osteonectin. Bone healing is aided by
vasculogenesis in the local tissue, and a suitable blood
supply during repair is considered essential if optimal
bone regeneration is to be achieved [38]. Inadequate or
inappropriate blood vessel development is associated with
decreased bone formation and bone mass [39]. PRGF is
known to release both angiogenic growth factors, includ-
ing VEGF, which has been implicated in the promotion of
angiogenesis and bone repair after injury and in cartilage
maturation and resorption [38], and anti-angiogenic
proteins, such as PF4 and endostatins. The ratio of these
factors under local conditions might determine the efficacy
of the treatment. Furthermore, the application of TGF-b1
and PDGF to osteoblasts induces additional VEGF
synthesis [40,41]. Given that TGF-b1 contained in PRGF
stimulates VEGF synthesis, its application at the time of
surgery will enhance the regenerative capacity of
bone tissue.
Another therapeutic approach involves the combi-
nation of PRP with different bone matrices. There are
several review articles describing the use of PRPwith both
mineral and organic bone matrices [27,42]. One potential
benefit of this combination is the improved handling and
adaptation of the matrix to the injured tissue because the
fibrin acts as a biological glue to hold together the matrix
particles. Moreover, early vascular invasion is a key factor
in bone allograft or xenograft incorporation, which
reduces complications related to slow and incomplete
integration. For example, Aghaloo et al. evaluated a
natural deproteinized bovine bone, known as Bio-Ossw,
with and without PRP in rabbit cranial defects and
observed significant histomorphometric improvement at
one, two and four months with the addition of PRP
compared with Bio-Ossw alone [43]. In another study,
b-tricalcium phosphate was assayed alone or in combi-
nation with PRP in the canine mandible. The histomor-
phometric results confirmed more intense bonewww.sciencedirect.comregeneration in the early healing phase following the
administration of PRP [44]. Recently, other authors have
reported on the benefits of treating intrabony periodontal
defects with PRP combined with bone mineral in
controlled clinical trials [45,46].
Soft-connective-tissue injuries
Soft-tissue disorders, including tendon, ligament and joint
capsular injuries, represent 45% of all themusculoskeletal
injuries reported each year in the USA, with a high
incidence among sport practitioners [47]. The importance
of this problem is substantial because the field of sports
medicine influences millions of people, from athletes to
people who participate in recreational sport or simply
people who use exercise to stay healthy and active. It is
now estimated that tendon injuries account for between 30
and 50% of all injuries related to sports [48,49] and these
often require surgical treatment. In these situations, the
application of innovative biological tools, such as platelet-
rich therapies, together with the surgical procedure might
enable surgeons to enhance and accelerate reconstruction
and repair of musculoskeletal tissues, affording new
opportunities for improving the outcome and reducing
the costs.
To address these issues, our group evaluated the effects
of the growth factors released by platelets on tendon cell
biology, to test the therapeutic potential of PRGF [50]. The
pool of released growth factors increased the in vitro
proliferation of human tendon cells significantly and
stimulated them to produce angiogenic factors such as
VEGF and hepatocyte growth factor (HGF) [51]. This
might be particularly relevant in the tendon repair
process, assuming that the reduced blood supply to the
tendon is associated with its low healing capability.
Moreover, HGF is a potent anti-fibrotic agent that might
reduce the formation of scarring around tendon tissue,
which is correlated with inferior repair quality [52]. Using
a common strategy, we also cultured tendon cells on
autologous fibrin matrices, mimicking the in vivo con-
ditions of the cells. Our results show that the use of
platelet-rich fibrin matrices is a safe and effective strategy
to accelerate tendon cell proliferation, stimulate the
synthesis of type I collagen and promote neovasculariza-
tion both in vitro and in vivo [53]. Interestingly, although
high levels of TGF-b1 are released upon activation of
PRGF, no signs of fibrosis were observed in the animal
models, perhaps because other biological mediators
secreted by the fibrin matrices or the platelets might
counteract this effect [53]. Anterior cruciate ligament
(ACL) surgery is an example of where current basic
research has a clinical application. Here, the injured
ligament is removed by arthroscopic surgery and the joint
is reconstructed with a tendon graft into which PRGF had
been injected [54]. Using this procedure, Sanchez et al.
reported enhanced healing with less complications and
improved fixation of the graft within the bone tunnels in a
retrospective clinical trial involving 100 patients [54].
Factors delivered from a PRGF-impregnated graft pro-
mote neovascularization [53], thereby favoring the remo-
deling of the graft that is essential for reproducing the
mechanical functions of the native ligament. In our
Review TRENDS in Biotechnology Vol.24 No.5 May 2006232experience, the surgical management of tendons in
combination with autologous platelet-rich therapies has
shown promising results. In another retrospective study,
PRGF applied during the open surgical repair of the
Achilles tendon in athletes showed an enhanced clinical
outcome and functional recovery compared with a
matched group that followed conventional surgery. Fur-
thermore, the cross-sectional area of tendons in the
platelet-rich group was significantly reduced, suggestive
of a more physiological repair (M. Sanchez et al.,
unpublished data).
Tissue engineering and cell therapy
Tissue engineering applies biological, chemical and
engineering principles in the development of functional
substitutes designed to meet the needs of each individual
patient and repair site [55]. In the past few years, several
research groups have explored the feasibility of using
platelet-rich matrices as tissue engineering scaffolds. In
most of these approaches, mesenchymal stem cells (MSCs)
have been combined with PRP with the aim of enhancing
bone regeneration. One potential advantage of this
MSC–PRP mixture is that it is simultaneously osteogenic,
osteoconductive and osteoinductive due to the bone-
forming capacity of MSCs and the presence of secreted
growth factors in the three-dimensional fibrin scaffold.
The platelet-rich scaffold also shows excellent biodegrad-
ability, commensurate with new bone formation. This
makes PRP different from other classical matrices, such as
tricalcium phosphate ceramics or coral scaffolds, which
virtually do not degrade during the first few weeks after
implantation. Additionally, this MSC–PRP mixture is
autologous, non-toxic and exhibits excellent plasticity.
Based on these principles, Ito and co-workers studied
the potential of a MSC–PRP mixture compared with
autogenous bone, Bio-Ossw and PRP alone to increase the
rate of bone formation in mandible defects of dogs. The
combination of cells and PRP provided greater bone
maturation and early-stage bone regeneration, as shown
by both histological examination and the testing of
mechanical properties compared with the rest of the
treatments [56]. Yamada et al. have previously reported
that a MSC–PRP combination induced well-formed
mature bone and neovascularization compared with a
control group. Furthermore, their data demonstrated that
PRP enabled MSC proliferation without deforming cell
structure, and that it was an excellent vehicle to hold and
deliver cells to correct or reconstruct bone defects in a
clinical setting [57]. In a further step, the MSC–PRP
combination was used for alveolar bone augmentation,
with the simultaneous placement of implants in three
human patients. This procedure gave rise to stable
implants with minimal invasiveness [58]. The therapeutic
potential of this tissue-engineered treatment has also
been proven, successfully, in three cases of distraction
osteogenesis of the long bones, leading to the conclusion
that marrow-derived osteoblast-like cells and PRP could
shorten the treatment period and lessen the associated
complications by accelerating new bone formation [59].
Interestingly, the soluble factors released from a
platelet-rich fibrin scaffold can be a powerful substitutewww.sciencedirect.comfor fetal calf serum (FCS) in the culture of different cells
such as MSCs. In fact, the use of FCS should be minimized
because it can be a potential source of prion or virus
transmission [60,61]. The presence of PRP significantly
increases the proliferation of stromal stem cells, reducing
the time and cost of culture and improving the safety [62].
This might be advantageous for clinical situations such as
the reconstruction of massive bone defects. Furthermore,
another advantage of this treatment is that cells return to
their normal rate of proliferation once the PRP is
withdrawn, which is an obligatory safety requirement if
the cells are to be transplanted into humans. The culture
potential of PRGF supernatants has also been observed,
successfully, by our group for the expansion of mature cells
such as tenocytes [50,51].Other applications of PRP
Ulceration of the lower limbs is a common complication of
a wide spectrum of pathologies that cause a negative
impact on the quality of life of affected patients and results
in O85 000 lower-extremity amputations each year in the
USA. Under these conditions, the application of platelet-
rich-derived therapies gives ground for optimism. In fact,
the material released from platelets has shown efficacy in
a retrospective cohort study involving 26 599 patients
[63]. Furthermore, the effectiveness and safety of a
platelet-rich preparation for the treatment of diabetic
foot ulceration has recently been reported [64]. The
therapeutic use of PRP has also been extended to other
fields, including facial plastic surgery, eye surgery and
cosmetic surgery. Because of its haemostatic properties, it
has been demonstrated that the platelet-rich preparation
is effective in sealing capillary beds during surgery and
thereby controlling bleeding [65]. In addition, it decreases
postoperative complications and avoids the re-exploration
of the patients, which is cost effective. This approach
opens a new and emerging field of wound pharmacology
that represents an exciting advance in plastic
surgery therapeutics.Conclusion
The use of preparations derived from autologous PRP
enables the local and progressive delivery of growth
factors and proteins providing unique properties for tissue
remodeling, wound healing and angiogenic promotion.
Consequently, PRP has been used in many different fields,
including orthopedic and maxillofacial surgery, sports
medicine, bone reconstruction, tissue engineering and
cosmetic and dental implant surgery. However, there are
still important challenges that need to be addressed. First,
it is necessary to compare the diverse, platelet-rich
products available commercially and to determine how
differences in their preparation and use affect their final
biological efficacy. Furthermore, procedures need to be
standardized and additional, well-designed studies and
clinical trials are needed to evaluate the potential
therapeutic impact of PRP in medicine and surgery and
to avoid controversial results [27,42,66]. The ability to
address all these challenges will enhance the potential of
this technology and extend its therapeutic applications.
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